Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001242447 | SCV001415537 | uncertain significance | Deficiency of hydroxymethylglutaryl-CoA lyase | 2024-02-23 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 140 of the HMGCL protein (p.Asn140Ser). This variant is present in population databases (rs148032473, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with HMGCL-related conditions. ClinVar contains an entry for this variant (Variation ID: 967513). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt HMGCL protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV003325555 | SCV004031923 | uncertain significance | not provided | 2024-07-03 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Genome- |
RCV001242447 | SCV004172272 | uncertain significance | Deficiency of hydroxymethylglutaryl-CoA lyase | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001835127 | SCV002094162 | uncertain significance | Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency | 2020-03-03 | no assertion criteria provided | clinical testing |